Loading stock data…
PRME
$3.41-0.14 (-3.81%)
Market ClosedLast close May 1
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Prime Medicine, Inc. in the Healthcare sector is trading at $3.41. The stock is currently 51% below its 52-week high of $6.94, remaining 16.0% below its 200-day moving average. Technical signals show neutral RSI of 41 and bearish MACD signal, explaining why PRME maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 41) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.41
Potential Upside
5%
Whystock Fair Value$3.58
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulom...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$714.99M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.67
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-166.41%
Volume
Today's trading volume
1.84M
Recent News
Prime Medicine (PRME) Appoints Svetlana Makhni as Chief Financial Officer
Prime Medicine, Inc. (NASDAQ:PRME) is one of the 10 Best Penny Stocks to Buy and Hold Under $5. On April 15, 2026, Prime Medicine, Inc. (NASDAQ:PRME) announced the appointment of Svetlana Makhni as Chief Financial Officer. In this role, she will lead the company’s financial strategy and operations, including investor relations, financial planning and analysis, […]
Prime Medicine (PRME) Focuses on Liver Franchise With $191.4M Cash Runway
Prime Medicine Inc. (NASDAQ:PRME) is one of the best new penny stocks to buy. On March 3, Prime Medicine reported its full-year 2025 financial results, highlighting a shift toward its in vivo liver franchise. The company ended the year with $191.4 million in cash, cash equivalents, and investments, providing a financial runway into 2027. Despite […]
Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates
Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of +13.39% and -63.64%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Jacob Funds Bets on Prime Medicine (PRME), a Next-Generation Gene Therapy Company
Jacob Funds, a mutual fund company, released its fourth-quarter 2025 investor letter. A copy of the same can be downloaded here. After an optimistic quarter, equity markets corrected slightly in November. Although overall economic growth has been robust throughout the year, recent divergent data on consumer spending and the labor market have put doubt on future […]
Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Lags Revenue Estimates
Vanda (VNDA) delivered earnings and revenue surprises of +78.85% and -2.78%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?